Increased Levels of GFAP in the Cerebrospinal Fluid in Three Subtypes of Genetically Confirmed Alexander Disease

Abstract

GFAP levels in the CSF were highly elevated in three genetically confirmed cases of Alexander disease clinically conforming with infantile, early and late juvenile forms. No other CSF abnormalities were detected. Assay of CSF-GFAP may prove to be a rapid and cost-effective screening test in clinical variants of Alexander disease and an indicator of GFAP gene mutations.

Alexander disease - GFAP - CSF analysis

References

• 1 Blennow K, Wallin A, Ågren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer's disease?.  Mol Chem Neuropathol. 1995;  26 231-245
• 2 Blennow M, Hagberg H, Rosengren L. Glial fibrillary acidic protein in the cerebrospinal fluid: a possible indicator of prognosis in full-term asphyxiated newborn infants?.  Pediatr Res. 1995;  37 260-264
• 3 Brockmann K, Dechent P, Meins M, Haupt M, Sperner J, Stephani U, Frahm J, Hanefeld F. Cerebral proton magnetic resonance spectroscopy in infantile Alexander disease.  J Neurol. 2003;  250 300-306
• 4 Ehlers S, Kyllerman M, Rosengren L. Analysis of glial fibrillary acidic protein in the cerebrospinal fluid of children investigated for encephalopathy.  Neuropediatrics. 1994;  24 129-133
• 5 Johnson A B, Brenner M. Alexander's disease: clinical, pathologic, and genetic features.  J Child Neurol. 2003;  18 625-632
• 6 Johnson A B. Alexander disease: A review and the gene.  Int J Dev Neurosci. 2002;  20 391-394
• 7 Kristiansdottir R, Uvebrant P, Rosengren L. Glial fibrillary acidic protein and neurofilament in children with cerebral white matter abnormalities.  Neuropediatrics. 2001;  32 307-312
• 8 Mignot C, Boespflug-Tanguy O, Gelot A, Dautigny A, Pham-Dinh D, Rodriguez D. Alexander disease: putative mechanisms of an astrocytic encephalopathy.  Cell Mol Life Sci. 2004;  61 369-385
• 9 Rosengren L E, Wikkelsø C, Hagberg L. A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults.  J Neurosci Meth. 1994;  51 197-204
• 10 Rosengren L E, Karlsson J ‐E, Karlsson J-O, Persson L I, Wikkelsø C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament proteins in CSF.  J Neurochem. 1996;  67 2013-2018
• 11 Li R, Johnson A B, Salomons G, Goldman J E, Naidu S, Quinlan R, Cree B, Ruyle S Z, Banwell B, D'Hooghe M, Siebert J R, Rolf C M, Cox H, Reddy A, Gutierrez-Solana L G, Collins A, Weller R O, Messing A, van der Knaap M S, Brenner M. Glial fibrillary acidic protein mutations in infantile, juvenile, and adult forms of Alexander disease.  Ann Neurol. 2005;  57 310-326
• 12 Lortie A, Lesage J, Montplaisir J, Brais B, Cossette P. Adult Alexander disease with autosomal dominant transmission: a distinct entity caused by a mutation in the glial fibrillar acid protein gene.  Arch Neurol. 2003;  60 1307-1312
• 13 Studahl M, Rosengren L, Günther G, Hagberg L. Difference in pathogenesis between herpes simplex virus type 1 encephalitis and tick-borne encephalitis demonstrated by means of cerebrospinal fluid markers of glial and neuronal destruction.  J Neurol. 2000;  247 636-642
• 14 Stumpf E, Masson H, Duquetta A, Berthelet F, McNabb J, Lortie A, Lesague J, Montpalisir J, Brais B, Cossette P. Adult Alexander disease with autosomal dominant transmission.  Arch Neurol. 2003;  60 1307-1312